Tradestie Institutional Equity Comparison Engine

ENTX vs SGMO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SGMO counters with relative strength in Valuation. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus SGMO at 0.4x Forward P/E and -175.5% operating margin (+88.4% YoY). In options structure, ENTX sits in CONSOLIDATION (47th %ile IV; Dealer Gamma Walls on Pro) against SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
ENTX N/M vs SGMO 0.4x Fwd P/E
Growth & Margin Winner ENTX
Op Margin 0.0% vs -175.5% ยท YoY -100.0% vs +88.4%
Momentum & Technical Winner ENTX
1Y +10.9% vs -76.0% ยท 52W Pos 65% vs 9%
Options & Structure Winner ENTX
CONSOLIDATION (47th %ile IV) vs UNCLASSIFIED (71st %ile IV)
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.04
-2.25% 1D
Market Cap $560.7M
1M Return +13.43%
1Y Return +10.95%
Forward P/E N/M
Unified AI Score
48.1 / 100 HOLD
Tech 34.0 Fund 51.0 Flow 76.0 Mom 60.0
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTX +10.95% SGMO -76.04% Spread: +0.97 pp (ENTX Lead)

Pillar 3 Multi-Year Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ENTX Revenue SGMO Revenue ENTX Op. Margin SGMO Op. Margin Margin Edge
FY2022 $0M N/A -9714.2% N/A ENTX
FY2024 $0M N/A -5295.6% N/A ENTX
FY2025 $0M N/A -27450.0% N/A ENTX
Q1 '25 N/A $30M N/A -460.3% SGMO
Q1 '26 N/A $10M N/A -2215.4% SGMO
Q2 '25 N/A $70M N/A -97.5% SGMO
Q3 '25 N/A $0M N/A -6119.3% SGMO
Q4 '25 N/A $60M N/A -175.5% SGMO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTX (5) vs SGMO (4)
Institutional Metric ENTX SGMO Criterion Row Winner
Market Capitalization Scale $560.7M $55.9M Larger Scale ENTX
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio Valuation N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY) Growth -100.0% +88.4% Higher Growth SGMO
Operating Margin (TTM) Profitability 0.0% -175.5% Higher Margin ENTX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -138.9% -2891.8% Higher ROE ENTX
52-Week Range Position Momentum 65% ($1โ€“$4) 9% ($0โ€“$1) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 1.07ฮฒ ยท 46% Vol 1.49ฮฒ ยท 206% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 48.1 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTX vs SGMO Buy Guide
ENTX CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTX nor SGMO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.